Shanghai Kaibao Pharmaceutical (300039) — Tangible Net Worth Ratio
Shanghai Kaibao Pharmaceutical (300039) has a Tangible Net Worth Ratio of 96.4% as of September 2025. This metric is calculated by deducting intangible assets (CN¥164.90 Million) from net assets (CN¥4.55 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See Shanghai Kaibao Pharmaceutical (300039) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Shanghai Kaibao Pharmaceutical Tangible Net Worth Ratio (2006–2024)
This chart shows how Shanghai Kaibao Pharmaceutical's Tangible Net Worth Ratio has changed across 19 annual periods from 2006 to 2024. As of September 2025, the ratio stands at 96.4%, reflecting net assets of CN¥4.55 Billion with intangible assets of CN¥164.90 Million CNY. See 300039 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Shanghai Kaibao Pharmaceutical (2006–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for Shanghai Kaibao Pharmaceutical from 2006 to 2024, covering 19 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see 300039 company net worth.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 95.9% | CN¥4.10 Billion | CN¥168.80 Million | CN¥4.52 Billion | ▼ -3.0 pp |
| 2023 | 98.9% | CN¥4.03 Billion | CN¥45.11 Million | CN¥4.58 Billion | ▲ +0.1 pp |
| 2022 | 98.8% | CN¥3.76 Billion | CN¥44.23 Million | CN¥4.26 Billion | ▲ +0.2 pp |
| 2021 | 98.6% | CN¥3.04 Billion | CN¥42.90 Million | CN¥3.36 Billion | ▲ +0.3 pp |
| 2020 | 98.2% | CN¥2.58 Billion | CN¥45.26 Million | CN¥2.88 Billion | ▼ -0.1 pp |
| 2019 | 98.4% | CN¥2.57 Billion | CN¥41.33 Million | CN¥2.84 Billion | ▲ +0.1 pp |
| 2018 | 98.3% | CN¥2.49 Billion | CN¥42.12 Million | CN¥2.75 Billion | ▲ +0.2 pp |
| 2017 | 98.2% | CN¥2.37 Billion | CN¥43.75 Million | CN¥2.68 Billion | ▲ +0.2 pp |
| 2016 | 97.9% | CN¥2.20 Billion | CN¥45.38 Million | CN¥2.53 Billion | ▲ +0.3 pp |
| 2015 | 97.7% | CN¥2.01 Billion | CN¥46.79 Million | CN¥2.43 Billion | ▲ +0.2 pp |
| 2014 | 97.5% | CN¥1.88 Billion | CN¥47.12 Million | CN¥2.12 Billion | ▲ +0.1 pp |
| 2013 | 97.4% | CN¥1.61 Billion | CN¥42.30 Million | CN¥1.77 Billion | ▼ -0.8 pp |
| 2012 | 98.2% | CN¥1.42 Billion | CN¥25.86 Million | CN¥1.56 Billion | ▲ +0.2 pp |
| 2011 | 98.0% | CN¥1.33 Billion | CN¥26.48 Million | CN¥1.45 Billion | ▲ +0.2 pp |
| 2010 | 97.8% | CN¥1.24 Billion | CN¥27.12 Million | CN¥1.37 Billion | ▲ +0.2 pp |
| 2009 | 97.6% | CN¥1.15 Billion | CN¥27.80 Million | CN¥1.35 Billion | ▲ +0.2 pp |
| 2008 | 97.4% | CN¥126.92 Million | CN¥3.32 Million | CN¥229.88 Million | ▼ -1.4 pp |
| 2007 | 98.7% | CN¥76.96 Million | CN¥965.65K | CN¥161.61 Million | ▲ +2.3 pp |
| 2006 | 96.4% | CN¥37.24 Million | CN¥1.32 Million | CN¥109.03 Million | — |